ADMA Biologics Class Action Lawsuit Overview
The ADMA class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ADMA securities. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918.
If you lost money on your ADMA Biologics investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why Is ADMA Biologics being Sued for Securities Fraud?
ADMA has been sued for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. The decline in AMDA’s stock price caused significant losses to investors.
ADMA is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics. ADMA’s flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.
During the relevant period, as alleged, ADMA was engaged in a de facto channel stuffing scheme to drive revenue growth in the face of waning demand for its flagship product, ASCENIV, and failed to disclose related party transactions.
Why did ADMA Biologics’ Stock Drop?
On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.
This news caused the price of ADMA stock to decline $2.26 per share, or 16.6%, from a closing price of $13.59 per share on March 23, 2026, to $11.33 per share on March 24, 2026. ADMA’s stock declined a further $1.70 per share, or 15%, the following day, to close at $9.63 per share on March 25, 2026.
Then, on March 26, 2026, Investing.com published an article titled “Cantor downgrades ADMA Biologics stock rating on short report concerns.” The article revealed investor disappointment in the company’s response to the Culper report and that Cantor Fitzgerald downgraded ADMA’s stock rating due to concerns raised in the Culper report and ADMA’s lack of clarity in its response to the report.
This news caused the price of ADMA stock to decline $1.34 per share, or 13.9%, from a closing price of $9.63 per share on March 25, 2026, to $8.29 per share on March 29, 2026.
ADMA Biologics (ADMA) Stock Chart
Image Caption: NASDAQ online chart showing the ADMA Biologics (ADMA) stock drops following the March 2026 revelations.
What is the ADMA Leadership Deadline?
You may ask the Court no later than August 10, 2026, to appoint you as Lead Plaintiff through counsel of your choice.
To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
How Do I Submit My Information?
If you lost money when ADMA Biologics securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
amccall@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
